Published in Clin Sci (Lond) on October 01, 1991
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science (1986) 15.84
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05
Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet (1989) 9.27
Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2007) 7.25
World-wide projections for hip fracture. Osteoporos Int (1997) 6.83
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil (1985) 5.34
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int (2004) 4.24
Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68
A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int (2012) 3.62
Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer (1997) 3.58
Bone densitometry in clinical practice. BMJ (1995) 3.48
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int (2008) 3.44
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Smoking and fracture risk: a meta-analysis. Osteoporos Int (2004) 3.08
Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int (2011) 3.04
General practitioners' perceptions of effective health care. BMJ (1999) 3.01
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg (1998) 2.75
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas (2009) 2.74
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol (1998) 2.70
A global representation of vitamin D status in healthy populations. Arch Osteoporos (2012) 2.69
The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int (1993) 2.66
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol (1993) 2.50
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Bone-density measurement. Lancet (1992) 2.38
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest (1997) 2.33
A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat Struct Biol (1997) 2.30
Multiple keratoses and squamous carcinoma after PUVA treatment of vitiligo. Clin Exp Dermatol (1996) 2.23
Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors. Ann Surg Oncol (2000) 2.21
Fracture risk following an osteoporotic fracture. Osteoporos Int (2003) 2.21
Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int (1999) 2.20
A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13
Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol (1994) 2.13
Characteristics of patients with orofacial granulomatosis. Oral Dis (2011) 2.12
Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ (1995) 2.10
Effects of interleukin-1 on bone turnover in normal mice. Endocrinology (1989) 2.06
Development and use of FRAX in osteoporosis. Osteoporos Int (2010) 2.04
Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med (1996) 2.00
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res (1999) 1.95
Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol (1995) 1.94
Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol (2001) 1.91
Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J Biol Chem (1991) 1.90
Nurse practitioners in general practice--an inevitable progression? Br J Gen Pract (1997) 1.89
Potential interventions for the prevention of childhood pneumonia in developing countries: a systematic review. Bull World Health Organ (1995) 1.88
Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. Lancet (1979) 1.87
Risk of vertebral fracture in women with rheumatoid arthritis. BMJ (1993) 1.87
Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med (1998) 1.84
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med (1998) 1.81
The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporos Int (1992) 1.81
Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res (1995) 1.79
Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int (2008) 1.77
A high incidence of vertebral fracture in women with breast cancer. Br J Cancer (1999) 1.74
Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos (2013) 1.72
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2010) 1.69
Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet (1980) 1.68
Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum (1993) 1.64
Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives. Br Med J (1977) 1.62
The distribution, determinants, and clinical correlates of vertebral osteophytosis: a population based survey. J Rheumatol (1999) 1.60
Uridine diphosphoglucose content of human erythrocytes: assessment by conversion to uridine diphosphoglucuronate. J Pediatr (1993) 1.59
Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int (1999) 1.59
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab (2000) 1.58
Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int (2012) 1.58
Potential interventions for the prevention of childhood pneumonia in developing countries: improving nutrition. Am J Clin Nutr (1999) 1.57
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum (1991) 1.56
Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin (2013) 1.55
Microinjection of ubiquitin: changes in protein degradation in HeLa cells subjected to heat-shock. J Cell Biol (1987) 1.52
Predictors of survival after laparoscopic radiofrequency thermal ablation of hepatocellular cancer: a prospective study. Surg Endosc (2005) 1.51
Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli. J Virol (2001) 1.50
Lack of c-erbB-2 oncoprotein expression in male breast carcinoma. J Clin Pathol (1991) 1.50
Is 24,25-dihydroxycholecalciferol a calcium-regulating hormone in man? Br Med J (1978) 1.49
Prevention of coronary heart disease with pravastatin. N Engl J Med (1996) 1.48
Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma--a report of the Children's Cancer Group. J Neurooncol (1998) 1.48
Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med (2000) 1.47
Use of diphosphonates in hypercalcaemia due to malignancy. Lancet (1990) 1.47
Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis? J Bone Joint Surg Br (1981) 1.46
The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int (1994) 1.46
Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis (1994) 1.46
Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2003) 1.45
Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int (2008) 1.45